Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the third part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, outlines alternative reimbursement or value-based contracting models that could be feasible in the short term, given CMS’ decision not to finalize coverage for obesity meds in 2026.

Innovative Paths to Obesity Medication Access

In the second part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, explains how dual-action metabolic therapies can address clinical or tolerability gaps observed in first-generation GLP-1s.

Can Dual Agonists Deliver Better Outcomes?

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, describes the immediate and long-term impacts of this potential levy on pharma imports.

The Ripple Effect of 200% Tariffs on US Drug Supply and Pricing

In the first part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, describes the US payer ecosystem’s level of preparedness to support broader access and long-term affordability for these therapies.

Coverage Gaps and Challenges Ahead for Obesity Drugs

In the final part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, details how he sees the competitive landscape evolving

How Competition, Access, and Reimbursement Will Shape the Next Wave of Innovation

In the fourth part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, outlines what he anticipates for the biosimilar adoption curve in key markets moving forward.

The Biosimilar Void

In the third part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, explains the strategies that manufacturers should adopt to balance investment in innovation with lifecycle management.

Balancing Innovation and Lifecycle Strategy in the Era of the IRA 

In the second part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, suggests how pharma companies should revise their market access and pricing models to align with the evolving landscape.

How Pharma Must Evolve in a Competitive Therapeutic Landscape

Articles

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and potentially, other IL-36–driven conditions.

LEO Pharma to Head Global Commercialization of Spevigo in $105M Deal with Boehringer Ingelheim

In the first part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, describes the process behind developing the “Global Use of Medicines Outlook Through 2029” report.

Market Access